Q1 Earnings Forecast for ENTA Issued By HC Wainwright

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Enanta Pharmaceuticals in a research note issued to investors on Tuesday, December 24th. HC Wainwright analyst E. Arce forecasts that the biotechnology company will post earnings of ($1.18) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($4.73) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q2 2025 earnings at ($1.32) EPS, Q3 2025 earnings at ($1.45) EPS, Q4 2025 earnings at ($1.58) EPS, FY2025 earnings at ($5.54) EPS, FY2026 earnings at ($7.90) EPS, FY2027 earnings at ($8.00) EPS and FY2028 earnings at ($7.36) EPS.

A number of other research analysts have also recently weighed in on the stock. JMP Securities restated a “market outperform” rating and issued a $21.00 price objective (down previously from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. Robert W. Baird cut their price objective on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $17.25.

Enanta Pharmaceuticals Stock Up 0.2 %

ENTA opened at $6.01 on Friday. Enanta Pharmaceuticals has a 52 week low of $5.70 and a 52 week high of $17.80. The business has a fifty day simple moving average of $9.15 and a 200-day simple moving average of $11.47. The firm has a market cap of $127.38 million, a P/E ratio of -1.10 and a beta of 0.49.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). The business had revenue of $14.60 million for the quarter, compared to analysts’ expectations of $17.99 million. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The business’s revenue for the quarter was down 22.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.33) earnings per share.

Insider Activity at Enanta Pharmaceuticals

In related news, CEO Jay R. Luly sold 5,142 shares of the company’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the completion of the sale, the chief executive officer now directly owns 801,638 shares of the company’s stock, valued at $6,461,202.28. This represents a 0.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 13.64% of the company’s stock.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several large investors have recently modified their holdings of the company. Bank of New York Mellon Corp raised its position in Enanta Pharmaceuticals by 13.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 73,841 shares of the biotechnology company’s stock valued at $958,000 after purchasing an additional 8,645 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in Enanta Pharmaceuticals in the 2nd quarter valued at about $35,000. Rhumbline Advisers raised its stake in Enanta Pharmaceuticals by 4.7% during the 2nd quarter. Rhumbline Advisers now owns 34,566 shares of the biotechnology company’s stock valued at $448,000 after acquiring an additional 1,548 shares during the last quarter. Quest Partners LLC lifted its position in Enanta Pharmaceuticals by 511.2% during the 2nd quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock worth $150,000 after acquiring an additional 9,692 shares during the period. Finally, American Century Companies Inc. increased its holdings in shares of Enanta Pharmaceuticals by 35.4% in the second quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company’s stock valued at $362,000 after purchasing an additional 7,287 shares during the period. 94.99% of the stock is owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.